Drug

Erenumab

Approved medicine

ClassCalcitonin gene-related peptide type 1 receptor antagonistResearchOngoing clinical research

Also known as Aimovig.

RxNorm2045613 ChEMBLCHEMBL3833329 ATCN02CD01UNIII5I8VB78VT

Active clinical trials

CALCRL

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)

Clinical trial2026-06-17Results expected Q3 2031 · ClinicalTrials.gov

Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study

Clinical trial2026-03-31Results posted · ClinicalTrials.gov

A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Clinical trial2025-10-23Results posted · ClinicalTrials.gov

A 12-week Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Once Monthly Subcutaneous Erenumab 70 mg in Adult Chronic Migraine Patients

Clinical trial2025-10-16Results posted · ClinicalTrials.gov

A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache

Clinical trial2025-09-19Results posted · ClinicalTrials.gov

Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Clinical trial2025-08-01Primary completion · ClinicalTrials.gov

Registry for Migraine - Structural and Functional Magnetic Resonance Imaging Before and After Erenumab Treatment

Clinical trial2025-07-22Primary completion · ClinicalTrials.gov

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Clinical trial2024-10-09Results posted · ClinicalTrials.gov

Phase 4, Open-label Study to Evaluate Treatment Satisfaction With Erenumab in Patients With Migraine

Clinical trial2024-09-19Results posted · ClinicalTrials.gov

Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)

Clinical trial2024-06-07Results posted · ClinicalTrials.gov

A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention

Clinical trial2024-02-21Results posted · ClinicalTrials.gov

Approval: Aimovig (EMA)

Regulatory2018-07-26EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Erenumab

Aliases & brands

Aimovig

RxNorm CUI

2045613

ChEMBL ID

CHEMBL3833329

ATC codes

N02CD01

UNII

I5I8VB78VT

Primary mechanism

Calcitonin gene-related peptide type 1 receptor antagonist

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Calcitonin gene-related peptide type 1 receptor

CALCRL · Q16602

ANTAGONISTCalcitonin gene-related peptide type 1 receptor antagonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2018-07-26

Latest approval

2018-07-26

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2018-07-26Approval

Approval: Aimovig (EMA)

Indication: Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.